TNFRSF8 and melanoma: Treg cells cultured in the presence of an anti-PD-L1 antibody showed upregulation of CD30 for all three human melanoma patients (Fig. 6j), suggesting that it is not the TME but anti-PD-1 activity that drives CD30 expression in tumor Treg cells.